Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye
Study Overview
A 4 weeks, Phase II, multicenter, randomized, double-masked, vehicle-controlled, parallel group study.
The study includes 12 weeks of follow-up to evaluate the safety and efficacy of recombinant human Nerve Growth Factor (rhNGF) eye drops solution versus vehicle in patients with moderate to severe dry eye (DE).
Further Reading:
The official study documentation is available here.
Contact Information:
For more information on the study or to enroll, please call Dr Goosey’s office at 713-558-8777.